Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Park, S. Y., Kang, J. H., Jeong, K. J., Lee, J., Han, J. W., Choi, W. S., Kim, Y. K., Kang, J., Park, C. G., & Lee, H. Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.25589 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“The blockage of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de novo resistance is a common feature in cancer patients [23,123].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 1×
“on tumor growth and an increase in OS [161].”
BackgroundVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38].”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Research works printed but not linked: 1
- 5. Domingues, G.; Fernandes, S.G.; Serpa, J. Dynamics of VEGF-A and its Receptors in Cancer Vascularization-An Overview. In Understand Cancer: Research and Treatment ; iConcept Press: Hong Kong, China, Chapter 3; 2015; ISBN 978-1-922227-386.
Cited by
Items 301–400 of 428
Research progress on vasculogenic mimicry in colorectal cancer: mechanisms and therapeutic
Zewei, J., & Haiyan, Z. (2026) · Cell Division · doi:10.1186/s13008-025-00171-z · Cited by 1
“Since conventional antiangiogenic therapies primarily target endothelial cells, they are ineffective against VM, explaining one of the key mechanisms behind clinical resistance to antiangiogenic drugs [6, 7].”
Maurya, A., Gaurav, A., Chauhan, V., & Verma, A. (2026) · Discover Medicine · doi:10.1007/s44337-026-00561-4 · Cited by 1
“Many of these substances are now undergoing preclinical research or early phase I clinical trials [150].”
Erianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway
Ruan, Y., Tang, L., Zhou, J., Li, C., & Wang, T. (2026) · Scientific Reports · doi:10.1038/s41598-026-40427-4 · Cited by 1
Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation
Alsfouk, A. A., Elkaeed, E. B., Elkady, H., Elgammal, W. E., Mahdy, H. A., Nofal, A. S., Eissa, I. H., Husein, D. Z., Ibrahim, I. M., Elkotamy, M. S., et al. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70280 · Cited by 2
“The development of effective cancer therapies remains a major challenge, particularly due to the critical role of angiogenesis in tumor growth (Lopes-Coelho et al. 2021; Lugano et al. 2020).”
Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target
Eissa, M. M., Ali, N. A.-H. F., & Skhawy, N. E. (2026) · Infectious Agents and Cancer · doi:10.1186/s13027-026-00747-6 · Cited by 1
“Consequently, interfering with angiogenesis unleashes the immune system [112].”
Disrupting the metastatic cascade: nanoparticle-based innovations in antimetastatic therapy
Meňhertová, T., Raudenská, M., Masařík, M., & Fojtů, M. (2026) · Nanoscale Horizons · doi:10.1039/d6nh00023a · Cited by 1
Effects of Tumor Microenvironment on Lung Cancer Stem Cells: Bidirectional Regulatory Mechanisms
Lai, H., Luo, R., Zou, W., Liu, X., Liu, M., Liu, M., & Zhang, J. (2026) · Cancer Medicine · doi:10.1002/cam4.71868 · Cited by 1
Ramali, D. P., Maphoso, T. M., Mulaudzi, T. V., Ambele, M. A., Maharaj, V. J., Mabeta, P., & Damane, B. P. (2026) · Future Oncology · doi:10.1080/14796694.2026.2665816 · Cited by 1
Greco, M. R., Fracasso, F., Cannone, S., Molfetta, D. D., Ardone, M., Cox, S. N., Ladogana, B. R., Abbrescia, D. I., Tullo, A., Ranieri, M., et al. (2026) · Cells · doi:10.3390/cells15100865 · Cited by 1
“One important common characteristic of many solid tumors is their abnormal, inefficient vasculature, which includes both blood and lymphatic vessels, and this feature contributes to a microenvironment characterized by low pHe, hypoxia, metabolic reprogramming, and immune evasion [15,85,86].”
Emerging molecular targets in gynaecologic cancers: clinical implications for personalized therapy
Shaik, B., Thokala, M., Shaik, F., Nakka, S., Pinjari, O. B., Marabathula, R. B., AL-Farga, A., & Anday, M. K. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12215-w · Cited by 1
“Nevertheless, the clinical effect of VEGF inhibition is not uniform, accompanied by a lack of reliable predictive biomarkers and common adaptive resistance, which is provoked by the stimulation of other pro-angiogenic pathways and microenvironmental remodelling [50].”
Reprogramming tumor angiogenesis in breast cancer: Mechanisms, challenges, and future directions
Mishra, B., Saha, S., Kumari, K., Mahapatra, S., Khanra, S., Malhotra, D., & Kundu, G. C. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154292 · Cited by 1
Zhou, Z., Yuan, T., Sun, J., Tian, C., Zhang, G., Fang, Y., Chen, Y., Xi, Y., Kong, J., Sun, X., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea5661 · Cited by 2
Tetrazole derivatives as potent immunomodulatory agents in tumor microenvironment
Pla-López, A., Cardá, M., & Falomir, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115668 · Cited by 1
“The activities obtained for these compounds were similar to reference compounds sorafenib, a VEGFR-2 inhibitor, and BMS-8, a PD-L1 inhibitor [20,21].”
Recent advances in conversion therapy schemes for stage IV gastric cancer
Liu, S., Zhang, K., & Luan, W. (2023) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000011 · Cited by 1
Jiang, H., Yang, L., Sun, Q., Wang, H., Li, W., Liu, Z., Li, L., Zhang, W., Zhang, Q., Huang, J., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141868 · Cited by 1
Lin, X., Chen, B., Xiao, X., Wang, R., Yao, W., & Li, A. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70040 · Cited by 1
“Most antiangiogenic agents aim to modulate angiogenic signaling pathways, especially focusing on the VEGF pathway [6, 7].”
State-of-the-Art in Antiangiogenic Agents in Cancer Therapy
Filippelli, A., Ciccone, V., Donnini, S., & Morbidelli, L. (2021) · Onco Therapeutics · doi:10.1615/forumimmundisther.2021039875 · Cited by 1
Chen, G., Tian, T., & Cai, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103512 · Cited by 1
Li, H., Yang, Z., Lü, X., Zhao, R., & Cheng, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332519 · Cited by 1
“Subsequently, extensive research has identi fi ed anti-angiogenic therapy as a cornerstone of modern cancer therapy (6).”
BackgroundExploring Novel Frontiers in Cancer Therapy
Țigu, A. B., & Tomuleasa, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061345 · Cited by 1
Tumor Angiogenesis May Be A Tragedy of the CommonsPreprint
Bhattacharya, R., Bukkuri, A., Gatenby, R. A., & Brown, J. S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5441855 · Cited by 2
Inorganic Nanoparticles in Anti-angiogenic Cancer Therapy
Mukherjee, S., & Madamsetty, V. S. (2022) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-031-11284-3_5
Nanomedicine: An Alternative Approach Towards Anti-angiogenic Cancer Therapy
Mukherjee, S., & Madamsetty, V. S. (2022) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-031-11284-3_3
Extracellular Matrix Remodeling Enzymes as Targets for Natural Antiangiogenic Compounds
Carrillo, P., García‐Caballero, M., Bernal, M., Manrique-Poyato, M. I., Martínez-Poveda, B., Quesada, A. R., & Medina, M. Á. (2022) · Biology of extracellular matrix · doi:10.1007/978-3-031-19616-4_6
Maintenance Treatment in Malignant Pleural Mesothelioma
Sobeih, M. E. (2022) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2022.20.556048
Correlation of Microvessel Density with Clinicothological Features of Hodgkin Lymphoma
Zulfikar, M. B., Murti, K., Liberty, I. A., Liberty, I. A., Dewi, C., & Rasyid, R. S. P. (2023) · Majalah Patologi Indonesia · doi:10.55816/mpi.v32i1.564
“10 One of the methods to quantify new blood vessels inside tumor tissues is by measuring microvessel density (MVD) with immunohistochemistry (IHC) staining.”
Kurz, F. T., & Hahn, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3163-8_20
Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy
-, N. K. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i01.11465
“[ 22] In recent years, dCas9, a modified version of the CRISPR-associated protein 9 (Cas9), has gained attention for its potential in epigenetic modulation [23].”
BackgroundProgramming Myeloid Cells with Chimeric Antigen Receptor Myeloid‐Based Therapies
Barnett, M., Gerber, M., Mukherjee, S., & Getts, D. R. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch24
Zhang, Y., Zhen, F., Sun, Y., Han, B., Wang, H., Zhang, Y., Zhang, H., & Hu, J. (2023) · Figshare · doi:10.6084/m9.figshare.24037204
Comprehensive Medicine Approach Towards Cancer Sufferers and Survivors: A Review
Yadav, R., Jakhar, R., Kumari, P., Yadav, D., & Kumar, R. (2024) · International Journal of Pharmaceutical and Bio-Medical Science · doi:10.47191/ijpbms/v4-i4-07 · Cited by 1
Heriz, M. H., Mahmood, A. A. R., Tahtamouni, L. H., Al-Sakhen, M. F., Kanaan, S. I., Saleh, K. M. M., & Yasin, S. R. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096307334240429050730
Introduction and barriers in cancer therapeutics
Loveleen, L., Nimesh, S., & Gupta, N. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15401-0.00014-2
Dayan, D., Ladany, H., Glaser, F., Foulkes, W. D., & Maruvka, Y. E. (2024) · Research Square · doi:10.21203/rs.3.rs-4507024/v1
Qiaolongbatu, X., Wu, Z., Qu, H., Shen, R., Wang, Y., Li, W., Zhou, C.-Y., Wang, Y., Fan, G., & Wu, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4866524
MATHEMATICS MODEL OF COMPACT TUMOR TO ANALYZE THE EFFECT ANTIANGIOGENIC THERAPY
Arfi, E., Putri, D. M., Wibarani, Y. G., & Rizka, N. (2024) · BAREKENG JURNAL ILMU MATEMATIKA DAN TERAPAN · doi:10.30598/barekengvol18iss3pp1585-1594
“Antiangiogenics are a class of therapies that use drugs to stop tumors from forming new blood vessels [7] .”
BackgroundKamyab, S. S., Moghe, A., Nandi, S. S., & Sawant, S. A. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.173159
“An increasing number of studies are being undertaken for the development of novel compounds to increase the effectiveness of anti-angiogenic therapies and overcome side effects [5].”
BackgroundSun, Y., Lu, Y., Li, X., He, Y., Yong, T. K., Keng, C. S., Yahaya, B. H., Liu, Y., & Lin, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07008-7
“For example, although endostatin has shown signi fi cant therapeutic effects in lung cancer, breast cancer, ovarian cancer, and lymphoma, it distributes easily to all tissues, with over 90% – 95% of endostatin accumulating in normal tissues and organs [5 – 8].”
BackgroundUnveiling the potential of combining photodynamic with anti-vascular therapy for cancer treatment
Sharma, S. K., Kaur, A., Batra, S., Marisetti, A. L., Kumar, L., & Tewari, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13937-6.00026-3
Gomez-Coral, M. I. (2024) · Journal of Cardiology & Cardiovascular Therapy · doi:10.19080/jocct.2024.19.556017
An Unsupervised Approach for Treatment Effectiveness Monitoring Using Curvature Learning
Sagreiya, H., Durot, I., & Akhbardeh, A. (2024) · Computers · doi:10.3390/computers13090227
Anti-Angiogenic Activity of Sabungai (Gynura procumbens) using a Cancer-induced Chicken Embryo
Aterrado, A. J. P. (2024) · Journal of Healthcare and Biomedical Science · doi:10.31098/jhbs.v2i2.2659
“Suppressing angiogenesis can starve tumors of the necessary nutrients, potentially arresting cancer progression (Lopes-Coelho et al., 2021).”
BackgroundVickers, E. (2024) · Wiley eBooks · doi:10.1002/9781119834090.ch4
M, V. V. R. R., Savitha., S., Akuthota, K., Khan, P. F., Navyatha, R., & Srithar, S. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.889975 · Cited by 3
Mangoni, A. A., Weerakoon, L., Ragavan, V. N., Jarzebska, N., Rodionov, R. N., & Tommasi, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22354-9.00002-4 · Cited by 1
Biotechnological approaches for the production of chemotherapeutics
Singh, N., Raghuwanshi, A. P., Khare, A., Siddiqui, J. A., & Shah, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22264-1.00010-4
2-Desaza-annomontine impedes angiogenesis by inhibiting CDC2-like-kinases and β-catenin activity
Zech, T. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.87954
Polloni, L., Costa, T. R., Morais, L. P., Borges, B. C., Teixeira, S. C., Fernandes, T. A. D. M., Correia, L. I. V., Bastos, L. M., Soares, A. M., Silva, M. J. B., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111361 · Cited by 1
NGÔ, T. M., Nagy, T., Szoboszlai, Z., Csikos, C., Dénes, N., Furka, A., Trencsényi, G., & Garai, I. (2024) · In Vivo · doi:10.21873/invivo.13814 · Cited by 1
“Recently, many anti-angiogenic therapies have demonstrated the ability to inhibit tumor growth, invasion, and metastasis (4).”
Umbilical cord-derived secretome induces apoptosis and reduces proliferation in cancer cells
Awan, S. J., Manuwar, M., Shahzadi, M., Hafeez, S., & Kausar, H. (2025) · International Journal of Applied and Experimental Biology · doi:10.56612/ijaaeb.v1i1.116
Mimetismo Vasculogénico: Mecanismo Alterno de Vascularización Adaptado por el Tumor
Herrera-Vargas, A. K., López, M. Á. B., Gómez, L. M., Zacapala-Gómez, A. E., Fausto, O. H., Fierro, C. A. M., Patiño-Morales, C. C., Sotelo-Leyva, C., Catalán, M. A. M., & Navarro‐Tito, N. (2025) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i6.15398
MiR-6747-5p suppresses angiogenesis in esophageal squamous cell carcinoma by targeting EGFL6
Huang, J., Xiao, Y., Li, C., Liu, S., Zhou, J., Song, Q., Wang, T., & Deng, N. (2025) · Molecular & cellular biomechanics · doi:10.62617/mcb1047
The role of monoclonal antibodies in the treatment of pancreatic and colon cancers
Dakshinamurthy, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00011-3
The Efficacy and Safety of Anlotinib in the Treatment of Gynecological Tumors: A Meta-Analysis
陈, 奋. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153882
Overview of Association Between Cardio-Oncology and Cardiovascular Medicine
(2025) · International Journal of Integrative Cardiology · doi:10.47275/2690-862x-149
Chromatin Remodeling in Cervical Tumor Cells Regulates Proangiogenic Genes
Bhat, S. M., Simha, N. L., Hegde, S., & Joshi, M. B. (2025) · Springer eBooks · doi:10.1007/978-981-96-3985-4_6
Du, J., Guo, B., Liu, J., Li, Z., Zhao, X., Shao, M., & Yang, F. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06210-0
“This mechanism is consistent with the observed improvement in OS among patients treated with antiangiogenic drugs (Lopes-Coelho et al. 2021).”
Pietrzak, J., & Knopik-Skrocka, A. (2025) · Tutoring Gedanensis · doi:10.26881/tutg.2025.1.02
Mechanisms of GIP in inhibiting cancer growth: Updates and perspectives
Wang, A., Ye, X., Mizejewski, G. J., & Zhang, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125824
Bouakel, L. E. (2025) · International Journal of Endovascular Treatment and Innovative Techniques · doi:10.61797/ijetit.v6i1.497
A novel vasculogenic mimicry-related nomogram predicts prognosis in hepatocellular carcinoma
Zhong, Y., Ding, F., Zhang, H., Zhang, D., Zhang, X., & Weng, S. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1431624
Li, Z., Li, J., Li, F., Liang, H., Wu, Z., Zhu, Y., Nong, J., Zhuo, T., Luo, P., He, L., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604179
“Anti-angiogenic therapy targeting angiogenesis-related factors is considered a promising treatment for malignant tumors (14, 15).”
Narmadha, B., Job, G. M., & Varshini, P. J. (2025) · Research Journal of Biotechnology · doi:10.25303/208rjbt043053
The frequency of p53 mutations in colorectal cancer patients
Aljhaemi, F., Allelish, A., Emaetig, F., Agoob, M., & Alqawi, O. (2025) · Journal of Cancer and Tumor Research · doi:10.52338/joctr.2025.4896
Journal of Cancer and Tumor Research
(2025) · Journal of Cancer and Tumor Research · doi:10.52338/joctr
Anti-angiogenic Compounds from Marine Organisms and Their Toxicological Effects: A Review
Kamna, R., Chillakuru, H. R., Shashank, C., Balde, A., & Nazeer, R. A. (2025) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-025-00679-z
“Most of the currently marketed anti-angiogenic formulations primarily target the partial to total suppression of VEGF and its wide family, which exhibit numerous comparable properties (Lopes-Coelho et al. 2021).”
Identifying Angiogenic Factors in Pediatric Choroid Plexus Papillomas
Sulaiman, N. B. S., Sng, S. M. Y., Merchant, K. Z., Ng, L. P., Low, D. C. Y., Seow, W. T., & Low, S. Y. Y. (2025) · NeuroSci · doi:10.3390/neurosci6030076
“However, temporal cancer research has highlighted that targeting VEGF alone is likely insufficient in the treatment of primary brain tumors [49,50].”
Angiogenesis and the Tumor Microenvironment
Murphy, J. F. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_87
Acín, M. P. A., Infante-Cossío, P., Sebastián, J. V. B., Nart, J., González, L. M. R., Poves, M. Z., Insausti, C. L., Espinosa, M. C., Carretero, J. L. C., & Diaz‐Guerra, G. M. (2025) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.20960/revosteoporosmetabminer.00107
Acebedo, I. J. B., Oronos, L., Pasicolan, K. M. D., & Quiape, A. M. (2025) · International Journal of Research and Innovation in Applied Science · doi:10.51584/ijrias.2025.1010000013
Cell‐Specific Functions of the BAI / ADGRB Subfamily of Adhesion G‐Protein Coupled Receptors
Alsharif, H. A., & Bhatnagar, S. (2025) · Comprehensive physiology · doi:10.1002/cph4.70068 · Cited by 1
“Blocking pro-angiogenic signaling pathways remains a major therapeutic strategy for cancer treat-ment (Lopes-Coelho et al. 2021).”
Evaluation of the anti-angiogenic property of uvaol: in silico, in vitro, and in ovo approaches
Simpauco, J. L., Billones, J. B., Vasquez, R. D., & Castillo, A. L. (2025) · Discover Pharmaceutical Sciences · doi:10.1007/s44395-025-00031-3
“The protein targets were determined by searching public databases, such as PubMed (https://pubmed.ncbi.nlm.nih.gov/) and identified from different l i t e r a t u r e reports [19–21].”
Zhang, Y., Zhen, F., Sun, Y., Han, B., Wang, H., Zhang, Y., Zhang, H., & Hu, J. (2023) · Figshare · doi:10.6084/m9.figshare.24037198
Liu, Y., Liang, J., Guo, G., Qiu, Y., Yu, L.-L., Tsim, K. W. K., Qin, Q.-W., Chan, G. K.-L., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26974404
Wang, H., Wu, Z., Fan, X., Wu, C., Lu, S., Geng, L., Stalin, A., Zhu, Y., Zhang, F., Huang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616470
Wang, H., Wu, Z., Fan, X., Wu, C., Lu, S., Geng, L., Stalin, A., Zhu, Y., Zhang, F., Huang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616467
Wang, H., Wu, Z., Fan, X., Wu, C., Lu, S., Geng, L., Stalin, A., Zhu, Y., Zhang, F., Huang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616473
Wang, H., Wu, Z., Fan, X., Wu, C., Lu, S., Geng, L., Stalin, A., Zhu, Y., Zhang, F., Huang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616464
Wang, H., Wu, Z., Fan, X., Wu, C., Lu, S., Geng, L., Stalin, A., Zhu, Y., Zhang, F., Huang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616461
Next-Generation SMART Nanocarriers: Impacting Cancer Theranostics Through Controlled Drug Delivery
Venugopal, D., Thantry, A. D. K., Gautam, S., Ramananthatheerthan, A., Marikani, K., & Dhanasekaran, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-3682-5_8
Curcumin ameliorates ulcerative colitis via inhibiting STAT3-mediated angiogenesis
Su, X., Zhou, Z., Zhu, A., Guo, Y., Jin, S., Zhang, M., & Hao, Y. (2025) · Archives of Medical Science · doi:10.5114/aoms/215559
“Pathological angiogenesis, however, often exhibits abnormal vessel structures and hyperper-meability, contributing to tumor progression and metastasis [22].”
Emerging role of Saikosaponin A in tumor therapy and tumor microenvironment immunomodulation
Zhang, L., Wang, C., Zhang, X., Lin, Z., & Chen, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119000
Against the Current: Celebrating Dr. Judah Folkman (1933–2008)
Fountain, S., & Hines, G. L. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001177
The potential of ancient medicine – using products from snails in treatment of oncology patients
Jasik, K. P., Kinasiewicz, J. K., Szlęzak, S., & Paluch, J. G. (2025) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/206989 · Cited by 1
Nutritional and Phytochemical Profile and Potential Anticancer Benefits of Amazonian Exotic Fruits
Lima, T. P. B., de Almeida, C. D. O. R. P., Lemos, I. D. M. L., de Souza, V. R., & Teodoro, A. J. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf307
Research Progress on Apatinib in the Treatment of Breast Cancer: From Mechanism to Clinical Practice
王杏丹 (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.163867
Li, Y., Zou, D., Hu, J., Ma, J., Bai, Y., Xiang, L., Maswikiti, E. P., Liu, B., Liao, L., Liu, J., et al. (2026) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2026.105442
Angiopoietin‐1, Angiopoietin‐2 and Vascular Endothelial Growth Factor Levels in Canine Leishmaniosis
Gültekin, G., Malatyalı, E., Tileklioğlu, E., Ertabaklar, H., Erdogan, S., Aşıcı, G. S. E., Oryaşın, A. G., Paşa, S., Ural, K. U. K., Erdoğan, H., et al. (2026) · Veterinary Medicine and Science · doi:10.1002/vms3.70871
Das, A., Bhat, R., & Jolly, M. K. (2026) · Applied Physics Reviews · doi:10.1063/5.0316218
Kuczkowski, T. A. (2026) · Journal of Oncology Research Review & Reports · doi:10.47363/jonrr/2026(7)194
Lim, Y. J., Son, D. W., Lee, E. J., Yu, C. S., Oh, Y. O., Cha, M. J., Kim, H., Kim, K., & Chang, S. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02801-7
“Angiogenesis is the formation of new blood vessels from pre-existing ones [22, 23].”
Régulation saisonnière de la plasticité cellulaire de l'hypothalamus mediobasal chez la brebis
Chevillard, P. (2022) · theses.fr (ABES) · doi:10.70675/6d5212ddzd1fcz4605z9e7az0c9212990874
Développement d'un ciblage moléculaire et d'un ciblage nanoparticulaire des dysfonctions vasculaires
Louis, B. (2022) · theses.fr (ABES) · doi:10.70675/4213c176z0905z4638z8db3z7ea83befc80b
Developmental and angiogenic safety profiles of novel pyridine-based chalcone
Hassan, A. F., Kheraldine, H., Idoudi, S., Hussein, O., Al-Thawadi, H., Khalil, A. A., Moustafa, A.-E. A., & Elhissi, A. M. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1780086
Modeling VEGF and GLUT1 Expression as Coadapted Foraging Strategies in CancerPreprint
Bhattacharya, R., Gatenby, R., & Brown, J. S. (2026) · bioRxiv · doi:10.64898/2026.04.14.718570
“This class includes clinically approved drugs such as bevacizumab and sunitinib, which target VEGF signaling and angiogenesis [67–69].”
The cancer nervous system rewiring oncology through neural disruption
Akl, M. M., & Ahmed, A. (2026) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20260201
Nagare, M. C., Gajbhiye, A. V., Shirsath, N. B., & Nirwan, R. S. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146570
Lin, S.-K., Li, T.-Q., Luo, X.-L., Zhang, Y.-C., Qian, J.-X., Huang, S.-L., Yang, M., Linghu, K., & Dong, J. (2026) · BMC Biotechnology · doi:10.1186/s12896-026-01166-6
“This dual inhibition is particularly relevant given the limited efficacy of single-agent anti-VEGF therapies like bevacizumab, which often trigger compensatory HIF-1α upregulation [24].”
Li, H.-Y., Peng, M.-Z., Tang, L.-H., Li, J.-A., Jin, Y., Liang, L. I. U., & Wang, W.-Q. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152505
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.